Cheng Hu

Cheng Hu is currently the Associate Director of Med Chem at Atomwise, a position they have held since 2021. Prior to this, they were a Senior Scientist at Denali Therapeutics from 2016-2021 and a Medicinal Chemist at Nurix, Inc. from 2015-2016. Cheng Hu began their career as a Scientist at Novartis in 2008, where they worked until 2015.

Throughout their career, Cheng Hu has been praised for their innovative thinking and ability to solve complex problems. Cheng has led several successful projects, most notably their work on identifying a “methyl pocket” to improve kinase specificities and their proposal and development of two novel inhibitors series featuring sp3 rich and low clogP. Cheng Hu has also established synthesis routes for various compounds, including a route to quickly map out SAR on 2 chemotypes. In addition, they have scaled up the synthesis of a lead compound for PK/PD and animal studies.

Cheng Hu’s work has had a significant impact on the field of medicinal chemistry and has helped to advance the development of new and improved treatments for various diseases. Cheng is an expert in their field and is highly respected by their peers. Cheng Hu’s dedication to their work and commitment to excellence are evident in all that they do.

Cheng Hu graduated with a Bachelor of Science in Chemistry from Nankai University. Cheng then went on to complete a Master of Engineering in Fine Chemicals at East China University of Science and Technology.

They work with Shahab Mortezaei - Associate Principal Scientist, Med Chem, Kyle Giesler - Senior Scientist, Med Chem. Their manager is Bill Thomas, Director, Med Chem.